Melanoma-associated antigen 1 and Melanoma-associated antigen 3 (MAGE-A1 and MAGE-A3) (MAGE-A1/A3)

Melanoma-associated antigen 1 (MAGE-A1) and Melanoma-associated antigen 3 (MAGE-A3) are members of the Type I MAGE family and are classified as cancer-testis antigens (CTAs) [1, 5]. Their expression is typically restricted to immune-privileged sites like the testis and placenta but is aberrantly reactivated in numerous malignancies, including melanoma, non-small cell lung cancer (NSCLC), and various carcinomas [5, 12]. In tumor cells, these proteins act as oncogenic drivers by serving as scaffolds for E3 ubiquitin ligases, such as TRIM28, which leads to the degradation of the tumor suppressor p53 and the energy sensor AMPK [9, 18]. This molecular mechanism promotes cell survival, proliferation, and resistance to apoptosis [12, 15]. Due to their high tumor specificity, they have been targeted by various immunotherapies, including recombinant protein vaccines (e.g., GSK1572932A), peptide vaccines, and TCR-engineered T cells [2, 5, 10]. However, clinical trials have faced challenges, such as the failure of the Phase III MAGRIT trial for MAGE-A3 vaccines and severe off-target toxicities in TCR-T therapies [4, 12]. Notable safety concerns include fatal cardiac toxicity due to TCR cross-reactivity with the muscle protein titin and neurological damage from cross-reactivity with MAGE-A12 in the brain [8, 11].

Other names

MAGE1MAGE3MAGE-A1MAGE-A3Melanoma antigen family A 1Melanoma antigen family A 3Cancer/testis antigen 1.1Cancer/testis antigen 1.3CT1.1CT1.3

Induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGE-A1 or MAGE-A3; adoptive transfer of TCR-engineered T cells for direct tumor lysis; epigenetic upregulation of antigen expression using demethylating agents [2, 3, 14].